Loading…
Equine Podiatry Solutions, LLC marketed an unapproved new animal drug called "Desmosphyrine" for treating laminitis in horses through their website and social media channels without FDA approval, violating the Federal Food, Drug, and Cosmetic Act. The company made disease-treatment claims on www.beatlaminitis.com and associated social media pages (Facebook and YouTube) establishing the product as a drug intended to cure, mitigate, treat, or prevent laminitis, including claims that it was "the first product that effectively treats acute laminitis" and "stops the matrix metalloproteinase from digesting collagen." The FDA identified these violations through website and social media reviews conducted in October 2021, November 2021, and March 2022, confirming the firm was distributing an unapproved veterinary drug product in interstate commerce.